Pfizer Inc.
NYSE:PFEDrug Manufacturers - General
-$0.71 today
- Market cap
- $159.94B
- Beta
- 0.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.32
- Dividend yield
- 6.82%
Volume 37.37M
Average 36.66M
PFE Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Pfizer Inc.NYSE: PFE
Other Working Capital · Q2 FY2026 · quarter ended Jun 2026
Other working capital declines year over year
Q2 FY2026 other working capital of $1.82B (cash outflow) fell 63.6% year over year, behind the -35.7% change in trailing-twelve-month other working capital. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at -7.3% a year.
Context
- Other working capital amounted to 8.3% of revenue in FY2025, up 6.6 pp from a year earlier.
- Other working capital grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -63.6% toward the trailing-twelve-month pace of -35.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (5.18B) USD
- Year-over-year change
- -379.9%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.18B) | -379.9% |
| FY2024 | 2024-12-31 | (1.08B) | -2.9% |
| FY2023 | 2023-12-31 | (1.05B) | +83.8% |
| FY2022 | 2022-12-31 | (6.5B) | -139.4% |
| FY2021 | 2021-12-31 | 16.5B | — |
Other Working Capital vs competitors
How PFE compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -35.7% is the 4th highest of 10, against a peer median of -80.8%.
- Other working capital amounts to 3.1% of revenue for PFE, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.82B USD | -429.2% | +109.4% | 11.9% | |
| LTM Jun 2026 | $4.8B USD | -38.9% | +148.0% | 6.0% | |
| LTM Jun 2026 | $3.31B USD | -456.5% | — | 6.7% | |
| LTM Jun 2026 | $2.98B USD | +0.8% | — | 4.6% | |
| LTM Sep 2026 | $2.95B USD | +931.3% | +84.9% | 4.7% | |
| LTM Jun 2026 | $1.99B USD | -35.7% | -7.3% | 3.1% | |
| LTM Jun 2026 | $1.12B USD | -800.6% | — | 2.0% | |
| LTM Jun 2026 | $1.02B USD | +119.4% | +41.8% | 1.5% | |
| LTM Jun 2026 | £777.4M GBP | -164.8% | -20.1% | 2.3% | |
| LTM Jun 2026 | $244M USD | -80.8% | +23.8% | 0.8% | |
| LTM Jun 2026 | €237.37M EUR | — | +118.9% | 0.5% | |
| Peer median (excluding PFE) | — | -80.8% | +84.9% | 3.5% | |
Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.46B | 31.4B | 2.17B | 8.05B | 7.79B |
| Depreciation & Amortization | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B |
| Deferred Income Tax | (4.29B) | (3.76B) | (3.44B) | (2.1B) | (2.13B) |
| Stock-Based Compensation | 1.18B | 872M | 525M | 877M | 799M |
| Change in Working Capital | 12.8B | (4.46B) | (2.17B) | (3.07B) | (5.35B) |
| Accounts Receivables | (3.81B) | 261M | 347M | (109M) | (263M) |
| Inventory | (1.13B) | 592M | (1.17B) | (854M) | 561M |
| Accounts Payables | 1.24B | 1.19B | (300M) | (1.02B) | (469M) |
| Other Working Capital | 16.5B | (6.5B) | (1.05B) | (1.08B) | (5.18B) |
| Other Non-Cash Items | (4.76B) | 150M | 5.33B | 1.97B | 4.01B |
| Operating Cash Flow | 32.58B | 29.27B | 8.7B | 12.74B | 11.71B |
| Capital Expenditures | (2.71B) | (3.24B) | (3.91B) | (2.91B) | (2.63B) |
| Acquisitions (Net) | (12M) | (23B) | (43.43B) | 7.04B | (6.93B) |
| Purchases of Investments | (47.61B) | (38.78B) | (31.18B) | (10.31B) | (14.65B) |
| Sales of Investments | 28.1B | 45.46B | 46.42B | 8.83B | 22.69B |
| Other Investing Activities | (306M) | 3.77B | (180M) | 0 | 165M |
| Investing Cash Flow | (22.55B) | (15.78B) | (32.28B) | 2.65B | (1.35B) |
| Debt Repayment | (1.1B) | (3.52B) | 35.95B | (7.16B) | (74M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2B) | 0 | 0 | 0 |
| Dividends Paid | (8.73B) | (8.98B) | (9.25B) | (9.51B) | (9.77B) |
| Other Financing Activities | 16M | (335M) | (632M) | (469M) | (459M) |
| Financing Cash Flow | (9.82B) | (14.83B) | 26.07B | (17.14B) | (10.3B) |
| Effect of Forex Changes | (60M) | (165M) | (40M) | (66M) | 49M |
| Net Change in Cash | 158M | (1.52B) | 2.45B | (1.81B) | 99M |
| Free Cash Flow | 29.87B | 26.03B | 4.79B | 9.84B | 9.08B |
Pfizer Inc.
NYSE:PFE
Intrinsic Alpha fair value
Locked
Current Price
$28.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.